Summit Therapeutics opens global Phase II trial of ivonescimab in advanced kidney cancer
Summit Therapeutics and partner Akeso announced the initiation of a multiregional Phase II study (SMT112-216) of ivonescimab, a bispecific PD‑1/VEGF antibody, in previously untreated advanced clear cell renal cell carcinoma. The randomized, open‑label trial will enroll approximately 100 patients at sites in the United States and China and will compare ivonescimab alone or in combination with cadonilimab or ipilimumab against a nivolumab‑plus‑ipilimumab standard‑of‑care arm. Summit’s CEO Robert W. Duggan and President Maky Zanganeh highlighted the study as a key part of the company’s strategy to expand ivonescimab across genitourinary cancers.
Why it matters
The study launch drove Summit’s share price up 7% to $15.69, reflecting investor optimism about the drug’s potential in a high‑unmet‑need cancer indication. The trial adds a new clinical data point that could influence future regulatory and commercial prospects for ivonescimab.
Key facts
- 1The trial is identified as SMT112‑216 (also AK112‑216, NCT07877194). finance.yahoo.com
- 2The study will enroll approximately 100 patients. finance.yahoo.com
- 3Clinical sites are located in the United States and China. finance.yahoo.com
- 4Ivonescimab is a novel investigational bispecific antibody targeting PD‑1 and VEGF. finance.yahoo.com
- 5The study is a randomized, open‑label Phase II design evaluating ivonescimab alone, ivonescimab + cadonilimab, ivonescimab + ipilimumab, and nivolumab + ipilimumab as comparator. finance.yahoo.com
- 6Summit Therapeutics announced the trial initiation on October 19 2026. finance.yahoo.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.